Jake Saklatvala

Jake Saklatvala

Auto-generated profile, based on publicly available information

Jake Saklatvala

Department of Medical and Molecular Genetics, School of Basic & Medical Biosciences, King's College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NDNick Dand
Nick Dand
PSPhilip E. Stuart
Philip E. Stuart
JBJohn Bowes
John Bowes
DEDavid Ellinghaus
David Ellinghaus
JNJoanne Nititham
Joanne Nititham
JEJames T. Elder
James T. Elder
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is not fully explained by variation at robustly identified risk loci. To refine the genetic map of psoriasis susceptibility we meta-analysed 18 GWAS comprising 36,466 cases and 458,078 controls and identified 109 distinct psoriasis susceptibility loci, including 46 that have not been previously reported. These include susceptibility variants at loci in which the therapeutic targets IL17RA and AHR are encoded, and deleterious coding variants supporting potential new drug targets (including in STAP2, CPVL and POU2F3). We conducted a transcriptome-wide association study to identify regulatory effects of psoriasis susceptibility variants and cross-referenced these against single cell expression profiles in psoriasis-affected skin, highlighting roles for the transcriptional regulation of haematopoietic cell development and epigenetic modulation of interferon signalling in psoriasis pathobiology.

7 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBrittany Mitchell
Brittany Mitchell
JSJake R. Saklatvala
Jake R. Saklatvala
NDNick Dand
Nick Dand
Fiona Alysa HagenbeekFiona Alysa Hagenbeek
Fiona Alysa Hagenbeek
XLXin Li
Xin Li
MSMichael A. Simpson
Michael A. Simpson
Acne vulgaris is a highly heritable skin disorder that primarily impacts facial skin. Severely inflamed lesions may leave permanent scars that have been associated with long-term psychosocial consequences. Here, we perform a GWAS meta-analysis comprising 20,165 individuals with acne from nine independent European ancestry cohorts. We identify 29 novel genome-wide significant loci and replicate 14 of the 17 previously identified risk loci, bringing the total number of reported acne risk loci to 46. Using fine-mapping and eQTL colocalisation approaches, we identify putative causal genes at several acne susceptibility loci that have previously been implicated in Mendelian hair and skin disorders, including pustular psoriasis. We identify shared genetic aetiology between acne, hormone levels, hormone-sensitive cancers and psychiatric traits. Finally, we show that a polygenic risk score calculated from our results explains up to 5.6% of the variance in acne liability in an independent cohort.

6 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RARosa Andres-Ejarque
Rosa Andres-Ejarque
HAHira Bahadur Ale
Hira Bahadur Ale
KGKatarzyna Grys
Katarzyna Grys
ITIsabella Tosi
Isabella Tosi
SSShane Solanky
Shane Solanky
DSDeborah Stocken
Deborah Stocken
Biologic therapies have transformed the management of psoriasis, but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. Here we perform in-depth immunomonitoring of blood immune cells of 67 patients with psoriasis, before and during therapy with the anti-TNF drug adalimumab, to identify immune mediators of clinical response and evaluate their predictive value. Enhanced NF-κBp65 phosphorylation, induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlates with lack of clinical response after 12 weeks of treatment. The heightened NF-κB activation is linked to increased DC maturation in vitro and frequency of IL-17+ T cells in the blood of non-responders before therapy. Moreover, lesional skin of non-responders contains higher numbers of dermal DC expressing the maturation marker CD83 and producing IL-23, and increased numbers of IL-17+ T cells. Finally, we identify and clinically validate LPS-induced NF-κBp65 phosphorylation before therapy as a predictive biomarker of non-response to adalimumab, with 100% sensitivity and 90.1% specificity in an independent cohort. Our study uncovers important molecular and cellular mediators underpinning adalimumab mechanisms of action in psoriasis and we propose a blood biomarker for predicting clinical outcome.


31 December 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
NDNick Dand
Nick Dand
CUChuin Y. Ung
Chuin Y. Ung
JSJake R. Saklatvala
Jake R. Saklatvala
MSMichael A. Simpson
Michael A. Simpson
JBJonathan N. Barker
Jonathan N. Barker
AOAlexandros Onoufriadis
Alexandros Onoufriadis

27 May 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RRRavi Ramessur
Ravi Ramessur
JSJake Saklatvala
Jake Saklatvala
MLMari Løset
Mari Løset
LTLaurent F. Thomas
Laurent F. Thomas
ABAshley Budu-Aggrey
Ashley Budu-Aggrey
CSCatherine H. Smith
Catherine H. Smith